The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 6,362,427 |
| Dividends earned on marketable securities held in trust account | 7,306,965 |
| Prepaid expenses | -202,381 |
| Due to sponsor | -104,762 |
| Accounts payable and accrued expenses | 29,008 |
| Net cash used in operating activities | -608,387 |
| Proceeds from promissory note - related party | 200,000 |
| Net cash provided by financing activities | 200,000 |
| Net change in cash | -408,387 |
| Cash - beginning of year | 438,174 |
| Cash - end of year | 29,787 |
Translational Development Acquisition Corp. (TDACW)
Translational Development Acquisition Corp. (TDACW)